EuroPCR 2017: Xeltis' Regenerated Heart Valve Shows Promising Early Preclinical Data
It may still be early days but Xeltis' second product from its Endogenous Tissue Restoration platform technology, an aortic valve scaffold, is showing promising results in animal studies. The data, presented at EuroPCR, showed that the bioresorbable aortic valve had good hemodynamic performance and fully functional valves in vivo six months after implantation.
You may also be interested in...
Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology.
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. News about trials of cardiovascular devices, especially novel heart valve replacement technologies, lead this month's edition, covering mid-May through mid-June.
The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.